PROCEPT BioRobotics is a surgical robotics company that manufactures and sells robotic systems delivering proprietary Aquablation therapy, a heat-free waterjet ablation technology for minimally invasive treatment of benign prostatic hyperplasia and other urologic conditions. The company generates revenue by selling its AquaBeam and HYDROS robotic platforms primarily to hospitals and ambulatory surgery centers, along with recurring revenue from disposable handpieces used during procedures; hospitals and outpatient facilities bill third-party payors, including Medicare and commercial insurers, for reimbursement of these procedures. With broad Medicare coverage and favorable commercial payor reimbursement covering approximately 95% of U.S. patients, the company addresses a large addressable market of millions of men eligible for surgical intervention, competing on clinical safety, efficacy across diverse anatomies, durable symptom relief, and reduced complication rates compared to alternative surgical approaches.